What did Shore Capital Markets say about Poolbeg Pharma?

On 13 July 2026 Shore Capital Markets published a note on Poolbeg Pharma (POLB 001) that highlighted first‑patient dosing in the TOPICAL study and did not publish a formal rating or price target.

Poolbeg Pharma — TickStock

Timeline

Poolbeg Pharma

14 stories · updated 6d ago

Poolbeg Pharma secures South Korean patent for POLB 001

07:41, 6 Oct 2026

Poolbeg dosed eight patients as TOPICAL trial gains momentum

08:02, 29 Sept 2026

Poolbeg doses eight patients in POLB 001 CRS trial

11:56, 28 Sept 2026

Poolbeg wins Israeli patent allowance for POLB 001

08:55, 21 Jul 2026

Poolbeg Pharma raises £3.5m as executive chair backs placing

11:42, 14 Jul 2026

Shore Capital flags TOPICAL trial start as key catalyst for Poolbeg

14:12, 13 Jul 2026

Poolbeg doses first patient in POLB 001 TOPICAL trial

09:03, 13 Jul 2026

Poolbeg Pharma wins South Africa patent for POLB 001 to 2038

09:03, 30 Jun 2026

Poolbeg Pharma granted European patent for POLB 001 in CRS

08:58, 16 Jun 2026

Poolbeg activates first site for POLB 001 TOPICAL trial

08:01, 11 Jun 2026

Poolbeg presents POLB 001 preclinical data showing CRS reduction and potential AML benefit

07:41, 11 Jun 2026

Poolbeg to present POLB 001 CRS data at EHA

09:40, 13 May 2026

Poolbeg Pharma wins Canadian patent for POLB 001 CRS use

16:19, 11 May 2026

Poolbeg Pharma says TOPICAL trial gets greenlight

11:06, 15 Apr 2026

IP Group leads £4m funding round for AI materials spin-out

08:29, 12 Oct 2026

Biotech

Genflow wins Japanese patent allowance for SIRT6 therapy

12:41, 9 Oct 2026

Biotech

Sareum signals intention to launch equity capital raise

09:32, 8 Oct 2026

Biotech

OKYO Pharma enrolls first patients in Phase 3 neuropathic corneal pain trial

13:29, 6 Oct 2026

Biotech

Avacta raises £12.5m in placing and subscription

07:27, 6 Oct 2026

Biotech

Health & Bio Today: Fusion Antibodies refreshes platform after margin turnaround, Molecule Group

17:03, 5 Oct 2026

Biotech

Fusion Antibodies relaunches website to sharpen customer focus

08:26, 5 Oct 2026

Regulation & Governance

Cardiogeni shares suspended on delayed annual accounts

09:57, 1 Oct 2026

Biotech

Imaging Biometrics builds US pipeline, rebrands core platform as IB Vista

08:54, 1 Oct 2026

Biotech

Eden Research wins US label expansion for Mevalone

12:07, 29 Sept 2026

Poolbeg Pharma is a clinical-stage biopharmaceutical company developing cancer immunotherapy treatments and obesity therapies. Its lead asset aims to prevent serious side effects in cancer immunotherapies, potentially expanding treatment access beyond specialist centers.

Sector: Biotech
Market: AIM

Insight

What patent did Poolbeg Pharma receive on 11 May 2026?

On 11 May 2026, Poolbeg Pharma received a Canadian patent covering the use of p38 MAPK inhibitors, including POLB 001, to prevent cytokine release syndrome triggered by cancer immunotherapy.

Updated 6 Oct 2026

Insight

When did Poolbeg Pharma expect the interim readout for its TOPICAL trial?

Poolbeg Pharma expected an interim readout for its TOPICAL trial in late summer 2026, per management guidance.

Updated 6 Oct 2026

Insight

What cash balance did Poolbeg Pharma report at 30 June 2026 and did it have any debt?

Poolbeg Pharma reported cash balances of approximately £4.8 million at 30 June 2026 and the company remained debt‑free.

Updated 16 Jul 2026

Insight

How much did Cathal Friel personally subscribe in Poolbeg Pharma's July 2026 placing?

Cathal Friel personally subscribed £250,000 in Poolbeg Pharma's July 2026 placing; this related‑party participation was disclosed as part of the capital raise.

Updated 16 Jul 2026

Insight

Where has Poolbeg Pharma’s CRS patent family been granted?

Poolbeg Pharma said its cancer immunotherapy-induced CRS patent family has been granted in Canada, Australia and Europe and allowed in Israel.

Updated 29 Sept 2026

Identifiers

Ticker: POLB
Market: AIM
ISIN: GB00BKPG7Z60
LEI: 213800UZ8WJLWYHBFL52

Learn more on:

GLEIF Companies House

Timeline

Poolbeg Pharma

Poolbeg Pharma secures South Korean patent for POLB 001

Poolbeg dosed eight patients as TOPICAL trial gains momentum

Poolbeg doses eight patients in POLB 001 CRS trial

Poolbeg wins Israeli patent allowance for POLB 001

Poolbeg Pharma raises £3.5m as executive chair backs placing

Shore Capital flags TOPICAL trial start as key catalyst for Poolbeg

Poolbeg doses first patient in POLB 001 TOPICAL trial

Poolbeg Pharma wins South Africa patent for POLB 001 to 2038

Poolbeg Pharma granted European patent for POLB 001 in CRS

Poolbeg activates first site for POLB 001 TOPICAL trial

Poolbeg presents POLB 001 preclinical data showing CRS reduction and potential AML benefit

Poolbeg to present POLB 001 CRS data at EHA

Poolbeg Pharma wins Canadian patent for POLB 001 CRS use

Poolbeg Pharma says TOPICAL trial gets greenlight

More in Biotech

IP Group leads £4m funding round for AI materials spin-out

Genflow wins Japanese patent allowance for SIRT6 therapy

Scancell widens annual loss

Sareum signals intention to launch equity capital raise

OKYO Pharma enrolls first patients in Phase 3 neuropathic corneal pain trial

Avacta raises £12.5m in placing and subscription

Health & Bio Today: Fusion Antibodies refreshes platform after margin turnaround, Molecule Group

Fusion Antibodies relaunches website to sharpen customer focus

Cardiogeni shares suspended on delayed annual accounts

Imaging Biometrics builds US pipeline, rebrands core platform as IB Vista

Eden Research wins US label expansion for Mevalone

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer